110
Participants
Start Date
June 27, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
Tislelizumab
Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
Albumin-Bound Paclitaxel
Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
Cisplatin
Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
Peking University School and Hospital Stomatology, Beijing
Affiliated Hospital of Hebei University, Baoding
Tangshan People's Hospital, Tangshan
The First Affiliated Hospital of Harbin Medical University, Harbin
Affiliated Hospital of Chifeng College, Chifeng
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot
The Hospital of Stomatology of Jilin University, Changchun
China Medical University School and Hospital Of Stomatology, Shenyang
Shandong Provincial Hospital, Jinan
The Affiliated Hospital of Qingdao University, Qingdao
First Hospital of Shanxi Medical University, Taiyuan
Shanxi Cancer hospital, Taiyuan
Tianjin First Central Hospital, Tianjin
Peking University Hospital of Stomatology
OTHER